OAC
UNCY icon

OMERS Administration Corp’s Unicycive Therapeutics UNCY Stock Holding History

OMERS Administration Corp’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-31,900
Closed -$210K – 1138
2026
Q1 		$210K Sell
31,900
-46,300
-59% -$303K ﹤0.01% 913
2025
Q4 		$451K Buy
+78,200
New +$417K ﹤0.01% 692

Other funds holding UNCY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

OMERS Administration Corp's UNCY Position: Q2 2026 in Review

OMERS Administration Corp sold out of Unicycive Therapeutics (UNCY) in Q2 2026, closing a stake of 31,900 shares — an estimated $210K sold.

OMERS Administration Corp first reported a position in UNCY in Q4 2025 and held it in 2 quarters. The position peaked at $451K in Q4 2025. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • OMERS Administration Corp reported no remaining Unicycive Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 31,900 Unicycive Therapeutics shares in Q2 2026, an estimated $210K.
  • OMERS Administration Corp first reported a position in Unicycive Therapeutics in Q4 2025 and held it in 2 quarters.
  • OMERS Administration Corp's Unicycive Therapeutics position peaked at $451K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.